Profile data is unavailable for this security.
About the company
Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Company’s main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.
- Revenue in HKD (TTM)5.83bn
- Net income in HKD589.74m
- Incorporated2010
- Employees3.64k
- LocationShanghai Henlius Biotech IncBuilding CNo. 1289 Yishan Road, Xuhui DistrictSHANGHAI 200233ChinaCHN
- Phone+86 2 133395800
- Fax+86 2 134611802
- Websitehttps://www.henlius.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Qyuns Therapeutics Co Ltd | 0.00 | -548.40m | 6.48bn | 331.00 | -- | 20.37 | -- | -- | -2.47 | -2.47 | 0.00 | 1.43 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | 1.64 | -69.52 | 0.5349 | -- | -- | -- | -70.28 | -- | -- | -- |
| Shanghai Fudan-Zhangjiang Bio-Pharm. Co | 874.03m | 110.37m | 6.63bn | 948.00 | 20.70 | 0.9028 | -- | 7.58 | 0.1073 | 0.1073 | 0.83 | 2.46 | 0.2852 | 1.44 | 1.62 | 921,968.80 | 3.59 | 7.03 | 4.35 | 9.05 | 91.40 | 92.17 | 12.59 | 17.26 | 3.94 | 568.37 | 0.0062 | 39.16 | -17.50 | 2.78 | -21.28 | -0.6326 | 20.49 | 0.00 |
| Tong Ren Tang Technologies Co Ltd | 7.32bn | 637.44m | 7.42bn | 4.10k | 11.63 | 0.9966 | 5.41 | 1.01 | 0.4977 | 0.4977 | 5.71 | 5.81 | 0.5212 | 0.9835 | 5.68 | 1,783,907.00 | 7.64 | 7.68 | 12.10 | 12.32 | 42.04 | 43.50 | 14.65 | 16.11 | 2.37 | -- | 0.1443 | 39.94 | 13.04 | 6.01 | 1.25 | -2.73 | -22.26 | 0.0178 |
| China Shineway Pharmaceutical Group Ltd | 4.88bn | 1.05bn | 8.18bn | 3.44k | 7.13 | 1.08 | 6.67 | 1.68 | 1.39 | 1.39 | 6.46 | 9.19 | 0.5073 | 1.44 | 6.31 | 1,419,723.00 | 10.89 | 8.03 | 14.15 | 9.77 | 75.15 | 74.55 | 21.47 | 17.87 | 2.98 | -- | 0.0411 | 36.29 | 14.32 | 11.94 | 34.14 | 13.89 | 0.6396 | 12.88 |
| Everest Medicines Ltd | 136.02m | -912.08m | 8.30bn | 432.00 | -- | 1.52 | -- | 61.02 | -2.92 | -2.92 | 0.4345 | 16.80 | 0.0203 | 2.25 | 4.57 | 314,849.80 | -13.63 | -30.52 | -15.06 | -33.14 | 72.67 | -- | -670.57 | -5,745.25 | 8.29 | -- | 0.0979 | -- | 884.46 | -- | -241.50 | -- | 4.65 | -- |
| Beijing Tong Ren Tang Chinese Medicine | 1.52bn | 540.39m | 8.76bn | 798.00 | 16.20 | 2.26 | 13.01 | 5.74 | 0.6456 | 0.6456 | 1.82 | 4.62 | 0.3522 | 0.6449 | 2.31 | 1,910,959.00 | 13.64 | 16.71 | 15.50 | 18.75 | 68.67 | 69.88 | 38.73 | 40.72 | 8.59 | -- | 0.0317 | 68.87 | -11.91 | 0.1459 | -16.33 | -1.43 | -16.30 | 7.49 |
| Cansino Biologics Inc | 372.82m | -1.60bn | 9.36bn | 1.49k | -- | 0.9172 | -- | 25.11 | -6.49 | -6.49 | 1.51 | 23.06 | 0.0332 | 2.37 | 0.4619 | 249,544.90 | -18.93 | -4.27 | -26.69 | -5.60 | -253.78 | -- | -569.97 | -27.72 | 1.86 | -- | 0.3381 | -- | -66.52 | 213.94 | -63.04 | -- | 30.60 | -- |
| Lepu Biopharma Co Ltd | 243.40m | -23.87m | 9.44bn | 429.00 | -- | 9.75 | 121.21 | 38.79 | -0.0144 | -0.0144 | 0.1467 | 0.5838 | 0.0917 | 1.06 | 1.62 | 567,355.40 | -1.23 | -- | -1.91 | -- | 87.45 | -- | -13.45 | -- | 0.7201 | 0.1388 | 0.4549 | -- | 1,347.16 | -- | 96.79 | -- | -- | -- |
| Shanghai Henlius Biotech Inc | 5.83bn | 589.74m | 9.55bn | 3.64k | 16.25 | 4.04 | 9.77 | 1.64 | 1.08 | 1.08 | 10.68 | 4.36 | 0.5731 | 1.95 | 9.10 | 1,602,109.00 | 5.80 | -8.59 | 12.47 | -14.14 | 72.64 | 71.77 | 10.12 | -27.37 | 0.3786 | 6.48 | 0.6512 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
| InnoCare Pharma Ltd | 797.67m | -681.81m | 10.13bn | 1.09k | -- | 1.17 | -- | 12.70 | -0.4043 | -0.4043 | 0.4727 | 4.38 | 0.073 | 1.39 | 3.39 | 732,479.50 | -6.38 | -13.41 | -8.08 | -15.36 | 82.61 | 85.99 | -87.42 | -172.16 | 4.13 | -- | 0.1582 | -- | 18.09 | 240.36 | 28.80 | -- | 66.20 | -- |
| AIM Vaccine Co Ltd | 1.28bn | -1.41bn | 10.16bn | 1.62k | -- | 2.58 | -- | 7.92 | -1.16 | -1.16 | 1.06 | 3.25 | -- | -- | -- | 789,745.20 | -- | -- | -- | -- | 75.88 | -- | -164.24 | -- | 0.7583 | -14.04 | 0.3158 | -- | -6.06 | -- | -307.07 | -- | -- | -- |
| Yichang Hec Changjiang Pharmactcl Co Ltd | 6.80bn | 2.15bn | 10.58bn | 4.62k | 4.91 | 1.23 | 4.36 | 1.56 | 2.45 | 2.45 | 7.73 | 9.74 | 0.5111 | 3.62 | 4.09 | 1,472,191.00 | 15.07 | 8.03 | 24.46 | 11.81 | 79.21 | 79.97 | 29.48 | 20.80 | 1.30 | 11.16 | 0.2475 | 15.81 | 68.08 | 20.18 | 2,501.24 | 16.15 | -11.50 | -- |
| Keymed Biosciences Inc | 382.45m | -388.13m | 11.02bn | 897.00 | -- | 3.42 | -- | 28.82 | -1.49 | -1.49 | 1.45 | 11.53 | 0.0906 | 0.7314 | 26.14 | 426,362.00 | -9.16 | -- | -10.05 | -- | 89.59 | -- | -101.04 | -- | 9.18 | -- | 0.123 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
| Luye Pharma Group Ltd | 6.63bn | 575.25m | 11.21bn | 5.27k | 19.39 | 0.8282 | 8.36 | 1.69 | 0.1537 | 0.1537 | 1.78 | 3.60 | 0.247 | 2.42 | 3.60 | 1,259,002.00 | 2.17 | 2.80 | 3.56 | 4.45 | 68.44 | 70.53 | 8.78 | 10.39 | 1.21 | 3.10 | 0.3931 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
| SciClone Pharmaceuticals (Holdings) Ltd | 3.41bn | 1.21bn | 11.44bn | 1.05k | 9.78 | 3.12 | 8.36 | 3.36 | 1.86 | 1.86 | 5.24 | 5.84 | 0.7585 | 3.56 | 3.83 | 3,245,979.00 | 26.97 | 27.09 | 33.34 | 36.32 | 74.67 | 76.06 | 35.55 | 35.43 | 4.50 | 33.70 | 0.01 | 22.98 | 14.76 | 17.50 | 31.16 | 15.96 | 25.65 | -- |
Data as of May 14 2024. Currency figures normalised to Shanghai Henlius Biotech Inc's reporting currency: Hong Kong Dollar HKD
2.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Qatar Investment Authority (Investment Management)as of 30 Jun 2023 | 2.84m | 1.74% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2023 | 347.30k | 0.21% |
| SSgA Funds Management, Inc.as of 04 Apr 2024 | 164.40k | 0.10% |
| Dimensional Fund Advisors LPas of 31 Jan 2024 | 32.80k | 0.02% |
| Baron Capital Management, Inc.as of 31 Dec 2022 | 1.01k | 0.00% |
| Mackenzie Financial Corp.as of 29 Feb 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 02 Apr 2024Source: FactSet Research Systems Inc.
